pain patch , page-19

I agree Jase,
MD is stacked for a small run to be attempted on the heels of a general update ( so far only small volume participating in it ), which is unlikely to spark the market if an exclusive development agreement with P&G failed to do so.


My expected Sept update should mention positive developments with each partner receiving a paragraph concerning each.
I still look forward to the wording as it will give further clues as to where we are within several programs.

We had very little information from management this year and the SP reflects this.


My personal expectations put an individual update of GSK in the second half of this year ( I doubt that meaningful information for the GSK partnership will be tucked away in a general update ), which in my opinion should move the price sustainably as it should contain positive outcomes from the Oral Health in vivo testing, so far only received indirectly through the notice of application extensions and US pharma division involvement earlier this year.